CN112239774B - 改进的测定方法 - Google Patents
改进的测定方法 Download PDFInfo
- Publication number
- CN112239774B CN112239774B CN202010970676.9A CN202010970676A CN112239774B CN 112239774 B CN112239774 B CN 112239774B CN 202010970676 A CN202010970676 A CN 202010970676A CN 112239774 B CN112239774 B CN 112239774B
- Authority
- CN
- China
- Prior art keywords
- ribosomal protein
- analyte
- reagent
- detection
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003556 assay Methods 0.000 title claims abstract description 68
- 230000001976 improved effect Effects 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 298
- 239000003153 chemical reaction reagent Substances 0.000 claims description 981
- 238000001514 detection method Methods 0.000 claims description 592
- 238000009739 binding Methods 0.000 claims description 481
- 230000027455 binding Effects 0.000 claims description 472
- 239000000523 sample Substances 0.000 claims description 466
- 239000012491 analyte Substances 0.000 claims description 462
- 108091034117 Oligonucleotide Proteins 0.000 claims description 272
- 238000004873 anchoring Methods 0.000 claims description 248
- 230000000295 complement effect Effects 0.000 claims description 215
- 239000002245 particle Substances 0.000 claims description 138
- 239000003446 ligand Substances 0.000 claims description 137
- 239000000427 antigen Substances 0.000 claims description 121
- 108091023037 Aptamer Proteins 0.000 claims description 119
- 108091007433 antigens Proteins 0.000 claims description 119
- 102000036639 antigens Human genes 0.000 claims description 119
- 108020003175 receptors Proteins 0.000 claims description 110
- 102000005962 receptors Human genes 0.000 claims description 110
- 239000003795 chemical substances by application Substances 0.000 claims description 107
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 100
- 239000002853 nucleic acid probe Substances 0.000 claims description 100
- 210000001808 exosome Anatomy 0.000 claims description 90
- 230000008685 targeting Effects 0.000 claims description 71
- 230000003321 amplification Effects 0.000 claims description 68
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 68
- 102100037904 CD9 antigen Human genes 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 239000007790 solid phase Substances 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 34
- 108090000790 Enzymes Proteins 0.000 claims description 34
- 238000003752 polymerase chain reaction Methods 0.000 claims description 30
- 238000011901 isothermal amplification Methods 0.000 claims description 26
- 230000005291 magnetic effect Effects 0.000 claims description 25
- 238000005096 rolling process Methods 0.000 claims description 24
- 238000007834 ligase chain reaction Methods 0.000 claims description 22
- -1 RplL Proteins 0.000 claims description 20
- 238000000149 argon plasma sintering Methods 0.000 claims description 19
- 230000001419 dependent effect Effects 0.000 claims description 19
- 238000005415 bioluminescence Methods 0.000 claims description 18
- 230000029918 bioluminescence Effects 0.000 claims description 18
- 230000031700 light absorption Effects 0.000 claims description 18
- 101710192508 30S ribosomal protein S2 Proteins 0.000 claims description 16
- 102000002278 Ribosomal Proteins Human genes 0.000 claims description 16
- 108010000605 Ribosomal Proteins Proteins 0.000 claims description 16
- 108060004795 Methyltransferase Proteins 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000006073 displacement reaction Methods 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 9
- 101710192511 30S ribosomal protein S3 Proteins 0.000 claims description 8
- 101710192513 30S ribosomal protein S4 Proteins 0.000 claims description 8
- 101710192514 30S ribosomal protein S5 Proteins 0.000 claims description 8
- 101710192510 30S ribosomal protein S7 Proteins 0.000 claims description 8
- 101710135899 50S ribosomal protein L15 Proteins 0.000 claims description 8
- 101710135886 50S ribosomal protein L16 Proteins 0.000 claims description 8
- 101710135889 50S ribosomal protein L17 Proteins 0.000 claims description 8
- 101710135890 50S ribosomal protein L20 Proteins 0.000 claims description 8
- 101710135892 50S ribosomal protein L21 Proteins 0.000 claims description 8
- 101710135891 50S ribosomal protein L22 Proteins 0.000 claims description 8
- 101710190982 50S ribosomal protein L5 Proteins 0.000 claims description 8
- 102100023777 60S ribosomal protein L31 Human genes 0.000 claims description 8
- 102100040768 60S ribosomal protein L32 Human genes 0.000 claims description 8
- 230000034659 glycolysis Effects 0.000 claims description 8
- 101710190989 50S ribosomal protein L4 Proteins 0.000 claims description 7
- 102100025222 CD63 antigen Human genes 0.000 claims description 5
- 102100027221 CD81 antigen Human genes 0.000 claims description 5
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 5
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 5
- 108090000202 Ribosomal protein L25 Proteins 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 102100038237 60S ribosomal protein L30 Human genes 0.000 claims 5
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 claims 5
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 claims 5
- 108010004103 Chylomicrons Proteins 0.000 claims 5
- 101710150697 Inositol monophosphatase 1 Proteins 0.000 claims 5
- 101710126181 Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 claims 5
- 102100029083 Minor histocompatibility antigen H13 Human genes 0.000 claims 5
- 102000005431 Molecular Chaperones Human genes 0.000 claims 5
- 101710154747 60S ribosomal protein L23a Proteins 0.000 claims 3
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims 2
- 108700030796 Tsg101 Proteins 0.000 claims 2
- 101150072717 Tsg101 gene Proteins 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 101710135862 50S ribosomal protein L23 Proteins 0.000 claims 1
- 101710135864 50S ribosomal protein L24 Proteins 0.000 claims 1
- 101710135882 50S ribosomal protein L25 Proteins 0.000 claims 1
- 101710135913 50S ribosomal protein L27 Proteins 0.000 claims 1
- 101710135912 50S ribosomal protein L28 Proteins 0.000 claims 1
- 101710135866 50S ribosomal protein L29 Proteins 0.000 claims 1
- 101710135915 50S ribosomal protein L30 Proteins 0.000 claims 1
- 101710135917 50S ribosomal protein L31 Proteins 0.000 claims 1
- 101710135916 50S ribosomal protein L32 Proteins 0.000 claims 1
- 101710135911 50S ribosomal protein L33 Proteins 0.000 claims 1
- 101710135933 50S ribosomal protein L34 Proteins 0.000 claims 1
- 101710135932 50S ribosomal protein L35 Proteins 0.000 claims 1
- 101710135934 50S ribosomal protein L36 Proteins 0.000 claims 1
- 102100028348 60S ribosomal protein L26 Human genes 0.000 claims 1
- 102100040131 60S ribosomal protein L37 Human genes 0.000 claims 1
- 102100030982 60S ribosomal protein L38 Human genes 0.000 claims 1
- 102100035988 60S ribosomal protein L39 Human genes 0.000 claims 1
- 102100026926 60S ribosomal protein L4 Human genes 0.000 claims 1
- 102100040623 60S ribosomal protein L41 Human genes 0.000 claims 1
- 101001080179 Homo sapiens 60S ribosomal protein L26 Proteins 0.000 claims 1
- 101000671735 Homo sapiens 60S ribosomal protein L37 Proteins 0.000 claims 1
- 101001127039 Homo sapiens 60S ribosomal protein L38 Proteins 0.000 claims 1
- 101000674326 Homo sapiens 60S ribosomal protein L41 Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 101001080597 Spinacia oleracea 50S ribosomal protein 5 alpha, chloroplastic Proteins 0.000 claims 1
- 101001110004 Tetrahymena thermophila 60S acidic ribosomal protein P1 Proteins 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000006174 pH buffer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 108010025387 ribosomal protein L39 Proteins 0.000 claims 1
- 108090000893 ribosomal protein L4 Proteins 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 abstract description 15
- 238000006243 chemical reaction Methods 0.000 description 90
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 88
- 108091093088 Amplicon Proteins 0.000 description 63
- 229960002685 biotin Drugs 0.000 description 48
- 239000011616 biotin Substances 0.000 description 48
- 150000007523 nucleic acids Chemical group 0.000 description 47
- 235000020958 biotin Nutrition 0.000 description 44
- 241000725303 Human immunodeficiency virus Species 0.000 description 43
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 39
- 101710205625 Capsid protein p24 Proteins 0.000 description 39
- 101710177166 Phosphoprotein Proteins 0.000 description 39
- 101710149279 Small delta antigen Proteins 0.000 description 39
- 238000005259 measurement Methods 0.000 description 34
- 230000008569 process Effects 0.000 description 32
- 108010090804 Streptavidin Proteins 0.000 description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 30
- 239000000463 material Substances 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 29
- 239000003431 cross linking reagent Substances 0.000 description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 23
- 239000000758 substrate Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 241000894007 species Species 0.000 description 20
- 108090001008 Avidin Proteins 0.000 description 19
- 238000003018 immunoassay Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 239000011148 porous material Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000003993 interaction Effects 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 13
- 230000006798 recombination Effects 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 238000000638 solvent extraction Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 108020004638 Circular DNA Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 239000011859 microparticle Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 108050003558 Interleukin-17 Proteins 0.000 description 8
- 102000013691 Interleukin-17 Human genes 0.000 description 8
- 102000004316 Oxidoreductases Human genes 0.000 description 8
- 108090000854 Oxidoreductases Proteins 0.000 description 8
- 102000004987 Troponin T Human genes 0.000 description 8
- 108090001108 Troponin T Proteins 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 102000013462 Interleukin-12 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000976 ink Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102100030704 Interleukin-21 Human genes 0.000 description 6
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- 108010065637 Interleukin-23 Proteins 0.000 description 6
- 102000013264 Interleukin-23 Human genes 0.000 description 6
- 102100021596 Interleukin-31 Human genes 0.000 description 6
- 101710181613 Interleukin-31 Proteins 0.000 description 6
- 102000017761 Interleukin-33 Human genes 0.000 description 6
- 108010067003 Interleukin-33 Proteins 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 230000003100 immobilizing effect Effects 0.000 description 6
- 108010074108 interleukin-21 Proteins 0.000 description 6
- 108010074109 interleukin-22 Proteins 0.000 description 6
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical class NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 6
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical class O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102000013498 tau Proteins Human genes 0.000 description 6
- 108010026424 tau Proteins Proteins 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 5
- 241000193738 Bacillus anthracis Species 0.000 description 5
- 108010075254 C-Peptide Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 5
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 4
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 101710096438 DNA-binding protein Proteins 0.000 description 4
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 108090000783 Renin Proteins 0.000 description 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000003154 D dimer Chemical group 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 3
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 3
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 101150031823 HSP70 gene Proteins 0.000 description 3
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 102000013534 Troponin C Human genes 0.000 description 3
- 102000013394 Troponin I Human genes 0.000 description 3
- 108010065729 Troponin I Proteins 0.000 description 3
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 3
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229940065181 bacillus anthracis Drugs 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 101150052825 dnaK gene Proteins 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108010052295 fibrin fragment D Chemical group 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910021389 graphene Inorganic materials 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- 239000000138 intercalating agent Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000012576 optical tweezer Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710146995 Acyl carrier protein Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
- 101710129634 Beta-nerve growth factor Proteins 0.000 description 2
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101100315385 Drosophila melanogaster tsg gene Proteins 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 101100088535 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) rplP gene Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 101710091439 Major capsid protein 1 Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102000005262 Sulfatase Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 2
- 102100039145 Trefoil factor 3 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 2
- 101100154843 Xenopus laevis twsg1-b gene Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 2
- 238000000475 fluorescence cross-correlation spectroscopy Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000008195 galaktosides Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004094 preconcentration Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101150050931 rplL gene Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 108060007951 sulfatase Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 101150060270 twsg1a gene Proteins 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- ISMWWJGHELLJIL-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;nickel Chemical compound [Ni].OC(=O)[C@@H](N)CC1=CNC=N1 ISMWWJGHELLJIL-JEDNCBNOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102100022785 Creatine kinase B-type Human genes 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101001047117 Homo sapiens Creatine kinase B-type Proteins 0.000 description 1
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Chemical group 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000689272 Senna sophera Species 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 108010072035 antithrombin III-protease complex Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010002829 beta-lactamase TEM-3 Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 101150114434 vanA gene Proteins 0.000 description 1
- 101150037181 vanB gene Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/125—Rolling circle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/514—Detection characterised by immobilisation to a surface characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010970676.9A CN112239774B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993581P | 2014-05-15 | 2014-05-15 | |
| US61/993,581 | 2014-05-15 | ||
| US201462013823P | 2014-06-18 | 2014-06-18 | |
| US62/013,823 | 2014-06-18 | ||
| US201462048489P | 2014-09-10 | 2014-09-10 | |
| US62/048,489 | 2014-09-10 | ||
| US201462049520P | 2014-09-12 | 2014-09-12 | |
| US62/049,520 | 2014-09-12 | ||
| US201462055093P | 2014-09-25 | 2014-09-25 | |
| US62/055,093 | 2014-09-25 | ||
| CN201580037961.2A CN106796218B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
| PCT/US2015/030925 WO2015175856A1 (en) | 2014-05-15 | 2015-05-15 | Improved assay methods |
| CN202010970676.9A CN112239774B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580037961.2A Division CN106796218B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112239774A CN112239774A (zh) | 2021-01-19 |
| CN112239774B true CN112239774B (zh) | 2024-12-03 |
Family
ID=54480726
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010970676.9A Active CN112239774B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
| CN201580037961.2A Active CN106796218B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
| CN202411604904.5A Pending CN119709943A (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580037961.2A Active CN106796218B (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
| CN202411604904.5A Pending CN119709943A (zh) | 2014-05-15 | 2015-05-15 | 改进的测定方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10408823B2 (enExample) |
| EP (1) | EP3143401A4 (enExample) |
| JP (5) | JP6695280B2 (enExample) |
| KR (3) | KR20250011724A (enExample) |
| CN (3) | CN112239774B (enExample) |
| AU (3) | AU2015259048B2 (enExample) |
| CA (1) | CA2948547A1 (enExample) |
| WO (1) | WO2015175856A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10114015B2 (en) | 2013-03-13 | 2018-10-30 | Meso Scale Technologies, Llc. | Assay methods |
| AU2014248759B2 (en) | 2013-03-13 | 2020-02-27 | Meso Scale Technologies, Llc. | Improved assay methods |
| EP3143401A4 (en) | 2014-05-15 | 2017-10-11 | Meso Scale Technologies, LLC | Improved assay methods |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| KR102003589B1 (ko) * | 2016-03-03 | 2019-07-24 | 성균관대학교산학협력단 | 생화학 분자 검출센서 및 다파장 형광을 이용한 생화학 분자 검출방법 |
| EP4047368A1 (en) * | 2016-05-19 | 2022-08-24 | Toppan Printing Co., Ltd. | Method and kit for target molecule detection |
| CN105969880B (zh) * | 2016-06-21 | 2020-08-07 | 北京农学院 | 一种肉类成分四重pcr的检测方法及应用 |
| CN105929151A (zh) * | 2016-06-30 | 2016-09-07 | 深圳市亚辉龙生物科技股份有限公司 | 前列腺特异性抗原同源异构体化学发光免疫检测试剂盒及其制备方法 |
| US10981174B1 (en) * | 2016-08-04 | 2021-04-20 | National Technology & Engineering Solutions Of Sandia, Llc | Protein and nucleic acid detection for microfluidic devices |
| AU2017370751B2 (en) | 2016-12-09 | 2023-11-09 | Ultivue, Inc. | Improved methods for multiplex imaging using labeled nucleic acid imaging agents |
| ES2928184T3 (es) * | 2016-12-12 | 2022-11-16 | Cepheid | Inmuno-PCR integrado y análisis de ácidos nucleicos en un cartucho de reacción automatizado |
| KR101964512B1 (ko) * | 2017-02-03 | 2019-04-01 | 경북대학교 산학협력단 | 항원 검출용 lc 마이크로액적 및 이를 이용한 바이오센서 및 이를 이용하여 항원을 검출하는 방법 |
| WO2018183876A1 (en) | 2017-03-31 | 2018-10-04 | Ultivue, Inc. | Dna-antigen exchange and amplification |
| DE102017005543A1 (de) * | 2017-06-13 | 2018-12-13 | Forschungszentrum Jülich GmbH | Verfahren zum Nachweis von Extrazellulären Vesikeln in einer Probe |
| WO2019104155A2 (en) * | 2017-11-22 | 2019-05-31 | The University Of Chicago | Chemical probe-dependent evaluation of protein activity and uses thereof |
| GB201720162D0 (en) | 2017-12-04 | 2018-01-17 | Univ Oxford Innovation Ltd | Method |
| JP6448826B1 (ja) | 2018-01-17 | 2019-01-09 | 国立大学法人東京工業大学 | エクソソームの製造方法及びその製造方法によって得られるエクソソーム |
| EP3760640A4 (en) * | 2018-02-27 | 2021-11-17 | Shimadzu Corporation | ANTIBODIES SPECIFICALLY RECOGNIZING THE N-TERMINAL END OF APP669-X, AND METHOD OF IMMUNOLOGICAL ASSAY |
| CA3093455A1 (en) | 2018-03-08 | 2019-09-12 | Meso Scale Technologies, Llc. | Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury |
| CN108562573B (zh) * | 2018-04-20 | 2020-01-03 | 青岛大学 | 一种基于二碳化三钛二维金属碳化物催化鲁米诺电化学发光探针的生物传感器及制备方法 |
| WO2019222708A2 (en) | 2018-05-17 | 2019-11-21 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| GB201810571D0 (en) * | 2018-06-27 | 2018-08-15 | Cs Genetics Ltd | Reagents and methods for the analysis of circulating microparticles |
| DE102018210710A1 (de) * | 2018-06-29 | 2020-01-02 | Robert Bosch Gmbh | Mikrofluidische Vorrichtung und Verfahren zum Nachweis eines Zielproteins einer biologischen Probe |
| WO2020037065A1 (en) * | 2018-08-17 | 2020-02-20 | Cellular Research, Inc. | Aptamer barcoding |
| JP7734964B2 (ja) * | 2018-09-26 | 2025-09-08 | ランプロジェン， インコーポレイテッド | タンパク質検出のためのデジタル増幅 |
| WO2020086751A1 (en) | 2018-10-23 | 2020-04-30 | Meso Scale Technologies, Llc. | Methods for isolating surface marker displaying agents |
| CN109444102B (zh) * | 2018-12-18 | 2021-03-23 | 济南大学 | 一种检测赭曲霉毒素a的荧光生物传感器及其制备方法和应用 |
| SG11202106924VA (en) | 2019-01-03 | 2021-07-29 | Meso Scale Technologies Llc | Compositions and methods for carrying out assay measurements |
| EP3998349A3 (en) * | 2019-03-01 | 2022-08-24 | Mercy Bioanalytics, Inc. | Compositions and methods for target protein detection on exosomes using proximal ligation |
| CN110082531B (zh) * | 2019-04-11 | 2022-04-22 | 南方医科大学南方医院 | 一种肿瘤外泌体纳米荧光检测试剂盒及其应用 |
| WO2021007099A1 (en) * | 2019-07-05 | 2021-01-14 | Ultivue, Inc. | Improved multiplexing method |
| EP4038386A4 (en) * | 2019-10-02 | 2023-11-08 | Nomic Bio Inc. | COLOCALIZATION BY LINKAGE SANDWICH ASSAY FOR MULTIPLEXES |
| TR201921980A2 (tr) * | 2019-12-27 | 2021-07-26 | Ege Üni̇versi̇tesi̇ | Anti̇bi̇yoti̇k di̇renç geni̇ tayi̇ni̇ i̇çi̇n elektroki̇myasal nanobi̇yosensöre dayali kullanima hazir tani ki̇ti̇ |
| US20230349907A1 (en) * | 2020-02-05 | 2023-11-02 | Pharmaxis Ltd. | Bioprobes for lysyl oxidases and uses thereof |
| US20230116205A1 (en) * | 2020-03-13 | 2023-04-13 | nPlex Biosciences Inc. | Multiplexed colocalization-by-linkage assays for the detection and analysis of analytes |
| CN115702043A (zh) * | 2020-04-15 | 2023-02-14 | 匡特里克斯公司 | 通过提高的捕获物体递送的与高灵敏度数字化测定相关的方法和系统 |
| WO2021222830A1 (en) | 2020-05-01 | 2021-11-04 | Meso Scale Technologies, Llc. | Viral serology assays |
| WO2021233186A1 (zh) * | 2020-05-17 | 2021-11-25 | 格物致和生物科技(北京)有限公司 | 基于虚拟分割技术的生物靶标数字化定量检测方法和系统 |
| EP4154008A1 (en) | 2020-05-19 | 2023-03-29 | Meso Scale Technologies, LLC | Methods, compositions, and kits for nucleic acid detection |
| US20230236179A1 (en) * | 2020-06-23 | 2023-07-27 | The Brigham And Women`S Hospital, Inc. | Single Molecule Assays for Ultrasensitive Detection of Biomolecules |
| AU2021299536A1 (en) | 2020-07-01 | 2023-02-16 | Meso Scale Technologies, Llc. | Compositions and methods for assay measurements |
| EP4182687A4 (en) * | 2020-07-20 | 2024-09-11 | Bio-Rad Laboratories, Inc. | IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR |
| US11603552B2 (en) | 2020-07-20 | 2023-03-14 | Mesa Photonics, LLC | Method for pathogen identification |
| WO2022032194A1 (en) | 2020-08-06 | 2022-02-10 | Singular Genomics Systems, Inc. | Methods for in situ transcriptomics and proteomics |
| WO2022032195A2 (en) | 2020-08-06 | 2022-02-10 | Singular Genomics Systems, Inc. | Spatial sequencing |
| EP4208720A2 (en) | 2020-09-04 | 2023-07-12 | Meso Scale Technologies, LLC | Methods for isolating central nervous system surface marker displaying agents |
| KR102573998B1 (ko) * | 2020-12-30 | 2023-09-04 | 주식회사 스타노스 | 위양성 신호가 제거된 항원 검출방법 및 키트 |
| WO2022187138A1 (en) | 2021-03-01 | 2022-09-09 | Meso Scale Technologies, Llc. | System and method for conducting a multiplexed assay |
| EP4330672A1 (en) | 2021-04-26 | 2024-03-06 | Meso Scale Technologies, LLC. | Methods for isolating and analyzing a target analyte encapsulated by a surface marker displaying agent |
| WO2022235764A1 (en) | 2021-05-05 | 2022-11-10 | Singular Genomics Systems, Inc. | Multiomic analysis device and methods of use thereof |
| US20220404360A1 (en) | 2021-05-21 | 2022-12-22 | Meso Scale Technologies, Llc. | Assays for viral strain determination |
| CN113406329B (zh) * | 2021-06-15 | 2024-05-28 | 江南大学 | 一种检测小分子物质的通用型适配体胶体金侧向层析试纸 |
| ES3042384T3 (en) * | 2021-06-17 | 2025-11-20 | Hoffmann La Roche | Method for immunosensing on a lipid layer using magnetic tunnel junctions |
| WO2022263523A1 (en) * | 2021-06-17 | 2022-12-22 | F. Hoffmann-La Roche Ag | Method for immunosensing on a lipid layer |
| EP4356133B1 (en) * | 2021-06-17 | 2025-07-30 | Roche Diagnostics GmbH | Method for immunosensing on a lipid layer using magnetic tunnel junctions ii |
| AU2022304570A1 (en) * | 2021-06-28 | 2024-01-18 | Meso Scale Technologies, Llc. | Methods, compositions, and kits for assay signal amplification |
| WO2023058624A1 (ja) * | 2021-10-08 | 2023-04-13 | コニカミノルタ株式会社 | 染色方法、評価方法および標本 |
| CN114350757B (zh) * | 2021-12-03 | 2023-08-15 | 西安交通大学 | 一种基于dna邻近组合编码扩增的细胞内成对染色质修饰成像方法 |
| IL313927A (en) | 2021-12-30 | 2024-08-01 | Meso Scale Technologies Llc | Methods for detection using electrochemiluminescence |
| EP4515233A2 (en) | 2022-04-29 | 2025-03-05 | Meso Scale Technologies, LLC | Methods for detecting and isolating extracellular vesicles |
| WO2023245184A1 (en) | 2022-06-17 | 2023-12-21 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| CN119585441A (zh) * | 2022-08-01 | 2025-03-07 | 凸版控股株式会社 | 评价方法、复合物及试剂盒 |
| WO2024064904A1 (en) | 2022-09-23 | 2024-03-28 | Meso Scale Technologies, Llc. | Orthopoxvirus serology assays |
| AU2023408595A1 (en) | 2022-12-20 | 2025-07-17 | Meso Scale Technologies, Llc. | Assay methods and kits |
| WO2024242845A1 (en) | 2023-05-24 | 2024-11-28 | Meso Scale Technologies, Llc. | Methods for assessing colorectal cancer using extracellular vesicles |
| WO2024249961A1 (en) | 2023-06-01 | 2024-12-05 | Singular Genomics Systems, Inc. | Methods and probes for detecting polynucleotide sequences in cells and tissues |
| WO2025049305A1 (en) | 2023-08-25 | 2025-03-06 | Meso Scale Technologies, Llc. | Viral strain serology assays |
| US20250208123A1 (en) * | 2023-12-20 | 2025-06-26 | Early Is Good, Inc. | Multi-Omic Integration Platform |
| WO2025173327A1 (ja) * | 2024-02-14 | 2025-08-21 | Ｎｅｃソリューションイノベータ株式会社 | 罹患死亡可能性予測モデル、罹患死亡可能性予測方法、罹患死亡可能性予測装置、プログラム、及び記録媒体 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854033A (en) * | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| WO2012160083A1 (en) * | 2011-05-24 | 2012-11-29 | Olink Ab | Multiplexed proximity ligation assay |
| CN105392895A (zh) * | 2013-03-13 | 2016-03-09 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN106796218A (zh) * | 2014-05-15 | 2017-05-31 | 中尺度技术有限责任公司 | 改进的测定方法 |
Family Cites Families (152)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4595661A (en) | 1983-11-18 | 1986-06-17 | Beckman Instruments, Inc. | Immunoassays and kits for use therein which include low affinity antibodies for reducing the hook effect |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5310687A (en) | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5026653A (en) | 1985-04-02 | 1991-06-25 | Leeco Diagnostic, Inc. | Scavenger antibody mixture and its use for immunometric assay |
| US5356774A (en) | 1986-04-16 | 1994-10-18 | The Trustees Of Columbia University In The City Of New York | Replicative RNA-based amplification/detection systems |
| US5147806A (en) | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
| US5591581A (en) | 1986-04-30 | 1997-01-07 | Igen, Inc. | Electrochemiluminescent rhenium moieties and methods for their use |
| US5635347A (en) | 1986-04-30 | 1997-06-03 | Igen, Inc. | Rapid assays for amplification products |
| US6165729A (en) | 1986-04-30 | 2000-12-26 | Hyperion Catalysis International, Inc. | Electrochemiluminescent reaction utilizing amine-derived reductant |
| US5656731A (en) | 1987-10-15 | 1997-08-12 | Chiron Corporation | Nucleic acid-amplified immunoassay probes |
| US5308754A (en) | 1988-03-21 | 1994-05-03 | Kankare Jouko J | Electrogenerated luminescence in solution |
| US4988617A (en) | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| US5093268A (en) | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| US5705402A (en) | 1988-11-03 | 1998-01-06 | Igen International, Inc. | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| US5200051A (en) | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
| US5324457A (en) | 1989-10-02 | 1994-06-28 | Board Of Regents, The University Of Tx System | Devices and methods for generating electrogenerated chemiluminescence |
| US5200314A (en) | 1990-03-23 | 1993-04-06 | Chiron Corporation | Polynucleotide capture assay employing in vitro amplification |
| JPH04222599A (ja) | 1990-04-20 | 1992-08-12 | Syntex Usa Inc | 二重受容体ポリヌクレオチド検定方法 |
| HUT64623A (en) | 1990-05-04 | 1994-01-28 | Chiron Corp | Protein and nucleinic acid samples and immunic essays containing them |
| US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
| JP3080178B2 (ja) | 1991-02-18 | 2000-08-21 | 東洋紡績株式会社 | 核酸配列の増幅方法およびそのための試薬キット |
| JPH0534345A (ja) | 1991-02-19 | 1993-02-09 | Tdk Corp | 化学発光を利用する抗原・抗体の測定方法 |
| US5665539A (en) | 1991-07-12 | 1997-09-09 | The Regents Of The University Of California | Immuno-polymerase chain reaction system for antigen detection |
| US6872816B1 (en) | 1996-01-24 | 2005-03-29 | Third Wave Technologies, Inc. | Nucleic acid detection kits |
| ZA929351B (en) | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
| EP0625213B1 (en) | 1992-10-09 | 1999-12-29 | VYSIS, Inc. | Assay methods |
| FR2699537B1 (fr) | 1992-12-18 | 1995-02-17 | Pasteur Institut | Protéine conférant une résistance de type inductible, à des glycopeptides, notamment chez des bactéries à gram-positif. Séquences de nucléotides codant pour cette protéine. |
| EP0682716A4 (en) | 1993-01-15 | 1999-10-27 | New York Health Res Inst | RNA ASSAYS USING BINARY RNA PROBES AND A RIBOZYME-LIGASE. |
| WO1994016108A1 (en) | 1993-01-15 | 1994-07-21 | The Public Health Research Institute Of The City Of New York, Inc. | Sensitive nucleic acid sandwich hybridization assays and kits |
| US6077668A (en) | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
| US5714320A (en) | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| CA2172248C (en) | 1993-09-22 | 2003-12-30 | John Kenten | Self-sustained sequence replication electrochemiluminescent nucleic acid assay |
| US5561043A (en) | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
| SE9400522D0 (sv) | 1994-02-16 | 1994-02-16 | Ulf Landegren | Method and reagent for detecting specific nucleotide sequences |
| US20070269799A9 (en) | 1994-06-22 | 2007-11-22 | Zhang David Y | Nucleic acid amplification methods |
| WO1995035390A1 (en) | 1994-06-22 | 1995-12-28 | Mount Sinai School Of Medicine Of The City University Of New York | Ligation-dependent amplification for the detection of infectious pathogens and abnormal genes |
| US5942391A (en) | 1994-06-22 | 1999-08-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method: ramification-extension amplification method (RAM) |
| USRE38442E1 (en) | 1994-06-22 | 2004-02-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method hybridization signal amplification method (HSAM) |
| US5786141A (en) | 1994-08-26 | 1998-07-28 | Bard; Allen J. | Electrogenerated chemiluminescence labels for analysis and/or referencing |
| US5660991A (en) | 1994-10-28 | 1997-08-26 | Lakowicz; Joseph R. | Long lifetime anisotropy (polarization) probes for clinical chemistry, immunoassays, affinity assays and biomedical research |
| SE9404166D0 (sv) | 1994-11-30 | 1994-11-30 | Pharmacia Biotech Ab | Multifunctional surfaces |
| US5866434A (en) | 1994-12-08 | 1999-02-02 | Meso Scale Technology | Graphitic nanotubes in luminescence assays |
| US5643713A (en) | 1995-06-07 | 1997-07-01 | Liang; Pam | Electrochemiluminescent monitoring of compounds |
| US5641623A (en) | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
| CN1192097C (zh) | 1995-03-10 | 2005-03-09 | 梅索磅秤技术有限公司 | 多阵列、多特异性的电化学发光检验 |
| US6673533B1 (en) | 1995-03-10 | 2004-01-06 | Meso Scale Technologies, Llc. | Multi-array multi-specific electrochemiluminescence testing |
| US6207369B1 (en) | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
| US5679519A (en) | 1995-05-09 | 1997-10-21 | Oprandy; John J. | Multi-label complex for enhanced sensitivity in electrochemiluminescence assay |
| US6319670B1 (en) | 1995-05-09 | 2001-11-20 | Meso Scale Technology Llp | Methods and apparatus for improved luminescence assays using microparticles |
| US5667974A (en) | 1995-06-07 | 1997-09-16 | Abbott Laboratories | Method for detecting nucleic acid sequences using competitive amplification |
| SE504798C2 (sv) | 1995-06-16 | 1997-04-28 | Ulf Landegren | Immunanalys och testkit med två reagens som kan tvärbindas om de adsorberats till analyten |
| US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
| EP0852004B1 (en) | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
| JP3974941B2 (ja) | 1995-11-21 | 2007-09-12 | イェール ユニバーシティ | 単分子セグメントの増幅および検出 |
| GB9606850D0 (en) | 1996-04-01 | 1996-06-05 | Univ Liverpool | An assay system and novel labelled compounds for use therwith |
| SE9601676D0 (sv) | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
| SE9603171D0 (sv) | 1996-08-30 | 1996-08-30 | Marek Kwiatkowski | Solid phase synthesis |
| JP2001523111A (ja) | 1997-05-05 | 2001-11-20 | サード ウェーブ テクノロジーズ，インコーポレーテッド | 構造体架橋オリゴヌクレオチドを使用した標的依存型反応 |
| US7314711B2 (en) | 1997-05-23 | 2008-01-01 | Bioveris Corporation | Assays employing electrochemiluminescent labels and electrochemiluminescence quenchers |
| FR2764381A1 (fr) | 1997-06-09 | 1998-12-11 | Univ De Neuchatel | Detecteur electrochimioluminescent |
| US6413783B1 (en) | 1997-09-18 | 2002-07-02 | Meso Scale Technologies, Llc | Assay sonication apparatus and methodology |
| US6054274A (en) | 1997-11-12 | 2000-04-25 | Hewlett-Packard Company | Method of amplifying the signal of target nucleic acid sequence analyte |
| JP4493844B2 (ja) | 1998-03-25 | 2010-06-30 | ランデグレン、ウルフ | 錠型（ｐａｄｌｏｃｋ）プローブのローリングサークル複製 |
| US6200531B1 (en) | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
| US8063190B2 (en) | 1998-06-02 | 2011-11-22 | Tom Robin Caine Boyde | Nucleic acid-linked conjugates and methods for making and using them |
| EP0962773A1 (en) | 1998-06-03 | 1999-12-08 | Mark Howard Jones | Electrochemical based assay processes instrument and labels |
| GB9815042D0 (en) | 1998-07-10 | 1998-09-09 | Imperial College | Detector |
| WO2000004193A1 (en) | 1998-07-20 | 2000-01-27 | Yale University | Method for detecting nucleic acids using target-mediated ligation of bipartite primers |
| CA2342838A1 (en) | 1998-09-15 | 2000-03-23 | Yale University | Molecular cloning using rolling circle amplification |
| US6214552B1 (en) | 1998-09-17 | 2001-04-10 | Igen International, Inc. | Assays for measuring nucleic acid damaging activities |
| US6136268A (en) | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
| CA2388780C (en) | 1999-11-12 | 2006-06-06 | Clinical Micro Sensors, Inc. | Binding acceleration techniques for the detection of analytes |
| US7309569B2 (en) | 1999-12-21 | 2007-12-18 | Ingeneus, Inc. | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes |
| US7306904B2 (en) | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| US6368801B1 (en) | 2000-04-12 | 2002-04-09 | Molecular Staging, Inc. | Detection and amplification of RNA using target-mediated ligation of DNA by RNA ligase |
| SE0001670D0 (sv) | 2000-05-04 | 2000-05-04 | Forskarpatent I Syd Ab | Mass-spectrometry-based biosensor |
| US6291187B1 (en) | 2000-05-12 | 2001-09-18 | Molecular Staging, Inc. | Poly-primed amplification of nucleic acid sequences |
| US6511809B2 (en) | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
| US6531283B1 (en) | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
| US6323009B1 (en) | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
| US7572642B2 (en) | 2001-04-18 | 2009-08-11 | Ambrigen, Llc | Assay based on particles, which specifically bind with targets in spatially distributed characteristic patterns |
| US6800608B2 (en) | 2001-06-22 | 2004-10-05 | Beckman Coulter, Inc. | Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator |
| DK1412725T3 (en) | 2001-06-29 | 2019-03-25 | Meso Scale Technologies Llc | Multi-well plates for LUMINESCENSE TEST MEASUREMENTS |
| US6808939B2 (en) | 2001-06-29 | 2004-10-26 | Igen International, Inc. | ECL labels having improved non-specific binding properties, methods of using and kits containing the same |
| GB2378245A (en) | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
| GB2382137A (en) | 2001-11-20 | 2003-05-21 | Mats Gullberg | Nucleic acid enrichment |
| EP1451356A1 (en) | 2001-11-23 | 2004-09-01 | Simon Fredriksson | Method and kit for proximity probing with multivalent proximity probes |
| AU2003222178A1 (en) | 2002-03-29 | 2003-10-13 | Nugen Technologies, Inc. | Single primer isothermal nucleic acid amplification-enhanced analyte detection and quantification |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| AU2003287527A1 (en) | 2002-12-18 | 2004-07-29 | Aclara Biosciences, Inc. | Single cell analysis of membrane molecules |
| US7192703B2 (en) | 2003-02-14 | 2007-03-20 | Intel Corporation, Inc. | Biomolecule analysis by rolling circle amplification and SERS detection |
| CN101410530B (zh) * | 2003-04-18 | 2013-03-27 | 贝克顿·迪金森公司 | 免疫-扩增 |
| US7195875B2 (en) | 2003-04-18 | 2007-03-27 | Beckman Coulter, Inc. | Oligonucleotide pairs for multiplexed binding assays |
| US20040248103A1 (en) | 2003-06-04 | 2004-12-09 | Feaver William John | Proximity-mediated rolling circle amplification |
| WO2005059509A2 (en) | 2003-12-12 | 2005-06-30 | Saint Louis University | Biosensors for detecting macromolecules and other analytes |
| CN101198707A (zh) | 2004-05-12 | 2008-06-11 | 内诺斯佩尔公司 | 基于生物条形码检测靶分析物 |
| SE0401270D0 (sv) | 2004-05-18 | 2004-05-18 | Fredrik Dahl | Method for amplifying specific nucleic acids in parallel |
| GB0421529D0 (en) | 2004-09-28 | 2004-10-27 | Landegren Gene Technology Ab | Microfluidic structure |
| US20060078894A1 (en) | 2004-10-12 | 2006-04-13 | Winkler Matthew M | Methods and compositions for analyzing nucleic acids |
| DE602006017192D1 (de) | 2005-04-12 | 2010-11-11 | Olink Ab | Verfahren zur herstellung von oligonukleotiden |
| AU2006249340A1 (en) * | 2005-05-26 | 2006-11-30 | Ensemble Discovery Corportion | Biodetection by nucleic acid-templated chemistry |
| US7883848B2 (en) | 2005-07-08 | 2011-02-08 | Olink Ab | Regulation analysis by cis reactivity, RACR |
| US20070161029A1 (en) * | 2005-12-05 | 2007-07-12 | Panomics, Inc. | High throughput profiling of methylation status of promoter regions of genes |
| US20070178934A1 (en) | 2006-01-30 | 2007-08-02 | Wen-Hua Sun | Mobile phone with automatic recording function |
| US8460879B2 (en) | 2006-02-21 | 2013-06-11 | The Trustees Of Tufts College | Methods and arrays for target analyte detection and determination of target analyte concentration in solution |
| GB0605584D0 (en) | 2006-03-20 | 2006-04-26 | Olink Ab | Method for analyte detection using proximity probes |
| US8313903B2 (en) | 2006-03-31 | 2012-11-20 | The Trustees Of Columbia University In The City Of New York | Binary DNA probe for fluorescent analysis of nucleic acids |
| EP2010475A2 (en) | 2006-04-27 | 2009-01-07 | Intezyne Technologies Incorporated | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| WO2009002537A1 (en) | 2007-06-25 | 2008-12-31 | Tufts University | Optical array device and methods of use thereof for screening, analysis and manipulation of particles |
| JP5503540B2 (ja) | 2007-08-30 | 2014-05-28 | トラスティーズ・オブ・タフツ・カレッジ | 溶液中の分析物濃度を決定する方法 |
| JP2009106220A (ja) | 2007-10-31 | 2009-05-21 | Genodive Pharma Kk | 基板上での等温増幅反応による標的塩基配列の捕捉及び検出方法 |
| ES2367232T3 (es) | 2007-11-21 | 2011-10-31 | Erasmus University Medical Center Rotterdam | Sondas de fret mejoradas y su uso. |
| FR2926162B1 (fr) * | 2008-01-03 | 2017-09-01 | Centre Nat De La Rech Scient - Cnrs | Procede de modification localisee de l'energie de surface d'un substrat |
| US8617806B2 (en) * | 2008-01-25 | 2013-12-31 | Hansabiomed Ou | Method to measure and characterize microvesicles in the human body fluids |
| JP5435878B2 (ja) | 2008-02-12 | 2014-03-05 | 富士フイルム株式会社 | 断片化抗体を標識物質に固定した標識粒子 |
| JP2009222712A (ja) | 2008-02-21 | 2009-10-01 | Univ Nagoya | メチシリン耐性ブドウ球菌の検出法、検出用試薬及び検出用キット |
| CN103399144B (zh) | 2008-02-25 | 2015-10-28 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
| US8465639B2 (en) * | 2008-04-09 | 2013-06-18 | Orafol Americas Inc. | Pin based method of precision diamond turning to make prismatic mold and sheeting |
| EP2294196A1 (en) * | 2008-06-06 | 2011-03-16 | Centre National de la Recherche Scientifique - CNRS | Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
| US8222047B2 (en) | 2008-09-23 | 2012-07-17 | Quanterix Corporation | Ultra-sensitive detection of molecules on single molecule arrays |
| US20100075862A1 (en) | 2008-09-23 | 2010-03-25 | Quanterix Corporation | High sensitivity determination of the concentration of analyte molecules or particles in a fluid sample |
| EP2358897B1 (en) | 2008-11-17 | 2015-02-25 | Headway Technologies, Inc. | Methods and compositions in particle-based detection of target molecules using linking molecules |
| EP2703816B1 (en) | 2008-11-21 | 2016-10-05 | Saint Louis University | Biosensor for detecting multiple epitopes on a target |
| US20100261292A1 (en) | 2009-04-10 | 2010-10-14 | Meso Scale Technologies, Llc | Methods for Conducting Assays |
| US8741559B2 (en) | 2009-04-24 | 2014-06-03 | Discoverx Corporation | Cellular assay employing detectable protein |
| KR101029343B1 (ko) | 2009-07-30 | 2011-04-13 | 한국과학기술연구원 | 면역분석 기반의 항원 검출용 키트 및 항원 검출 방법 |
| US9914963B2 (en) | 2009-09-28 | 2018-03-13 | Igor Kutyavin | Methods and compositions for detection of nucleic acids based on stabilized oligonucleotide probe complexes |
| JP5954876B2 (ja) | 2009-10-13 | 2016-07-20 | ナノストリング テクノロジーズ， インコーポレイテッド | ナノレポーターによるタンパク質の検出 |
| US8236574B2 (en) | 2010-03-01 | 2012-08-07 | Quanterix Corporation | Ultra-sensitive detection of molecules or particles using beads or other capture objects |
| US8415171B2 (en) | 2010-03-01 | 2013-04-09 | Quanterix Corporation | Methods and systems for extending dynamic range in assays for the detection of molecules or particles |
| WO2011143583A1 (en) | 2010-05-13 | 2011-11-17 | Illumina, Inc. | Binding assays for markers |
| WO2012006476A2 (en) | 2010-07-07 | 2012-01-12 | Aethlon Medical, Inc. | Methods and compositions for quantifying exosomes |
| GB201011971D0 (en) | 2010-07-15 | 2010-09-01 | Olink Ab | Methods and product |
| US10669569B2 (en) | 2010-10-15 | 2020-06-02 | Navinci Diagnostics Ab | Dynamic range methods |
| WO2012060083A1 (ja) | 2010-11-05 | 2012-05-10 | 株式会社ニコン | 照明装置、露光装置、プログラムおよび照明方法 |
| US9952237B2 (en) | 2011-01-28 | 2018-04-24 | Quanterix Corporation | Systems, devices, and methods for ultra-sensitive detection of molecules or particles |
| GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
| EP2500435B1 (en) | 2011-03-18 | 2016-09-21 | miacom Diagnostics GmbH | Identification of antibiotic resistance in micro organisms |
| GB201107863D0 (en) * | 2011-05-11 | 2011-06-22 | Olink Ab | Method and product |
| KR101329127B1 (ko) * | 2011-06-30 | 2013-11-14 | 한국생명공학연구원 | 올리고뉴클레오타이드 결합 항체를 이용한 당단백질 검증방법 |
| ES2700792T3 (es) | 2011-11-11 | 2019-02-19 | Eli N Glezer | Procedimientos de ensayo asistidos por coagente de unión |
| GB201201547D0 (en) | 2012-01-30 | 2012-03-14 | Olink Ab | Method and product |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014164594A1 (en) | 2013-03-11 | 2014-10-09 | Meso Scale Technologies, Llc. | Improved methods for conducting multiplexed assays |
| US10114015B2 (en) | 2013-03-13 | 2018-10-30 | Meso Scale Technologies, Llc. | Assay methods |
| CN108374052A (zh) | 2018-03-20 | 2018-08-07 | 徐州工程学院 | 用于生物芯片检测金黄色葡萄球菌的探针组序列 |
| CN113557309A (zh) | 2018-10-31 | 2021-10-26 | 斯坦福大学托管董事会 | 用于使用寡核苷酸缀合抗体检测细胞的方法和试剂盒 |
| CN120098057A (zh) | 2019-03-01 | 2025-06-06 | 中尺度技术有限责任公司 | 用于免疫方法的被电化学发光标记的探针、使用这类探针的方法和包含这类探针的试剂盒 |
| IL300973A (en) | 2020-09-02 | 2023-04-01 | Meso Scale Technologies Llc | Kits for detecting one or more target analytes in a sample and methods for making and using the same |
-
2015
- 2015-05-15 EP EP15793097.5A patent/EP3143401A4/en active Pending
- 2015-05-15 AU AU2015259048A patent/AU2015259048B2/en active Active
- 2015-05-15 JP JP2016567814A patent/JP6695280B2/ja active Active
- 2015-05-15 CN CN202010970676.9A patent/CN112239774B/zh active Active
- 2015-05-15 CA CA2948547A patent/CA2948547A1/en active Pending
- 2015-05-15 KR KR1020257001537A patent/KR20250011724A/ko active Pending
- 2015-05-15 KR KR1020237003878A patent/KR102757668B1/ko active Active
- 2015-05-15 CN CN201580037961.2A patent/CN106796218B/zh active Active
- 2015-05-15 WO PCT/US2015/030925 patent/WO2015175856A1/en not_active Ceased
- 2015-05-15 CN CN202411604904.5A patent/CN119709943A/zh active Pending
- 2015-05-15 KR KR1020167034329A patent/KR102497054B1/ko active Active
- 2015-05-15 US US15/311,309 patent/US10408823B2/en active Active
-
2019
- 2019-09-09 US US16/564,208 patent/US11525825B2/en active Active
-
2020
- 2020-04-21 JP JP2020075171A patent/JP7000493B2/ja active Active
-
2021
- 2021-12-07 AU AU2021282419A patent/AU2021282419B2/en active Active
- 2021-12-23 JP JP2021210002A patent/JP7256860B2/ja active Active
-
2022
- 2022-07-21 US US17/813,965 patent/US12411131B2/en active Active
-
2023
- 2023-03-31 JP JP2023059022A patent/JP7575516B2/ja active Active
-
2024
- 2024-10-17 JP JP2024181465A patent/JP2025020158A/ja active Pending
-
2025
- 2025-03-14 AU AU2025201868A patent/AU2025201868A1/en active Pending
- 2025-08-08 US US19/294,774 patent/US20250362291A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854033A (en) * | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| WO2012160083A1 (en) * | 2011-05-24 | 2012-11-29 | Olink Ab | Multiplexed proximity ligation assay |
| CN105392895A (zh) * | 2013-03-13 | 2016-03-09 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN105393118A (zh) * | 2013-03-13 | 2016-03-09 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN110055304A (zh) * | 2013-03-13 | 2019-07-26 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN110308272A (zh) * | 2013-03-13 | 2019-10-08 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN117288934A (zh) * | 2013-03-13 | 2023-12-26 | 中尺度技术有限责任公司 | 改进的测定方法 |
| CN106796218A (zh) * | 2014-05-15 | 2017-05-31 | 中尺度技术有限责任公司 | 改进的测定方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12411131B2 (en) | Assay methods | |
| US12163954B2 (en) | Assay methods | |
| HK40015589A (en) | Improved assay methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |